Opko Health promoted Adam Logal to Senior VP and CFO following the resignation of its top financial executive.<br />The Miami-based biotech and pharmaceutical company (NYSE: OPK) led by billionaire entrepreneur Dr. Phillip Frost had a big day on Tuesday as it announced the nationwide launch of its 4Kscore blood test for prostate cancer. Its stock closed up 39 cents, or 4.2 percent, to $9.17.<br />Logal replaces Juan F. Rodriguez, who will remain as consultant to Opko as he “pursues personal business interests,” according to the company. Logal has been Opko’s VP of finance, chief accounting officer and treasurer.<br />“Adam has been a key leader in our organization since our inception in 2007. His knowledge of our business, versatility as a finance leader and his strategic insights are valued by leaders across the company,” Frost said in a news release. “I am delighted that Adam will continue to help lead the company through our near term commercial opportunities and help position us for long-term success.”<br />Logal currently has a $235,000 base salary and now he can participate in the company’s executive bonus program.<br />Opko also named Arie Gutman as CEO of its new active pharmaceutical ingredient and chemical development division. Gutman is the founder of FineTech Pharmaceutical, which Opko acquired in late 2011.